Patents Assigned to EYE HOSPITAL, WENZHOU MEDICAL UNIVERSITY
  • Patent number: 12221418
    Abstract: Disclosed is a montelukast berberine double salt or composition with anti-inflammatory, antibacterial and immunomodulatory effects. Particularly, disclosed are a montelukast berberine quaternary ammonium salt with a structure as represented by formula (I), a double salt or a composition, a solvate, a hydrate, an isotope substitution or an isomer thereof.
    Type: Grant
    Filed: November 16, 2022
    Date of Patent: February 11, 2025
    Assignee: EYE HOSPITAL, WENZHOU MEDICAL UNIVERSITY
    Inventor: Wei Chen
  • Patent number: 12220411
    Abstract: Application of a PTGDS inhibitor in preparation of a drug for treating cataracts is provided. As an effective and selective PTGDS inhibitor, AT-56 competitively inhibits production of PGD2 by occupying a catalytic site of PTGDS. The PTGDS catalyzes synthesis of the PGD2 to cause an oxidative stress injury of human lens epithelial cells, thereby promoting occurrence and development of aging and opacity of a lens. By reducing apoptosis caused by the oxidative stress injury, a degree of the cataracts can be effectively reduced.
    Type: Grant
    Filed: October 8, 2023
    Date of Patent: February 11, 2025
    Assignee: THE EYE HOSPITAL OF WENZHOU MEDICAL UNIVERSITY
    Inventors: Jin Li, Jiasheng Liu, Yitong Xu, Mengchao Zhu, Haisen Sun
  • Publication number: 20250041211
    Abstract: The present invention discloses an ophthalmic preparation and an application thereof in the treatment of presbyopia. The ophthalmic preparation includes aceclidine and rebamipide. It is found and proved in the present invention for the first time that the aceclidine and the rebamipide are combined to produce a synergistic effect, the rebamipide can enhance an effect of the aceclidine and reduce related side effects, and the aceclidine can effectively produce a synergistic effect with the rebamipide to contract the pupillary sphincter and have a dosage effect. The ophthalmic preparation can effectively improve, alleviate or treat presbyopia, have a potential effect of slowing down the progression of the presbyopia course, and have a very good clinical application prospect.
    Type: Application
    Filed: October 22, 2024
    Publication date: February 6, 2025
    Applicant: EYE HOSPITAL, WENZHOU MEDICAL UNIVERSITY
    Inventor: Wei Chen
  • Publication number: 20250037794
    Abstract: The present invention belongs to the technical fields of biomedicine and gene detection, and particularly relates to a group of SNP markers related to myopia or high myopia and use thereof. Specifically, the SNP sites include an SNP site combination related to myopia or high myopia, comprising: one or more of rs10484690, rs117984746, rs1196455, rs143477571, rs143580489, rs189212243, rs2296651, rs2303221, rs2547319, rs26173, rs3817585, rs41303763, rs42688, rs61746299, rs78587889, and rs80094829.
    Type: Application
    Filed: October 13, 2024
    Publication date: January 30, 2025
    Applicants: EYE HOSPITAL, WENZHOU MEDICAL UNIVERSITY, CENTER OF OPTOMETRY INTERNATIONAL INNOVATION OF WENZHOU
    Inventors: Liangde Xu, Hong Wang, Jia Qu
  • Publication number: 20240165089
    Abstract: The present application relates to a method for treating myopia with vipocetine, which can effectively prevent myopia and/or control the progression of myopia while being safe and free of obvious side effects, having good prospects for clinical application.
    Type: Application
    Filed: January 19, 2024
    Publication date: May 23, 2024
    Applicant: EYE HOSPITAL, WENZHOU MEDICAL UNIVERSITY
    Inventors: Xiangtian Zhou, Sen Zhang, Jia Qu, Qinyuan Zheng
  • Patent number: 11419761
    Abstract: A glaucoma aqueous humor drainage device and a glaucoma aqueous humor drainage method, wherein the opening and closing of a pressure valve is controlled by the change in the pressure in a cavity of the valve. When the pressure in the intraocular pressure exceeds 12 mmHg, the valve is opened, and a drainage tube connected behind the valve drains the aqueous humor to the ocular surface, reducing the patient's discomfort and dry eyes, effectively draining the aqueous humor and avoiding scarring caused by embedding the device via a conjunctival flap and operation failure caused by increase of intraocular pressure caused by generation of filtering blebs.
    Type: Grant
    Filed: July 22, 2020
    Date of Patent: August 23, 2022
    Assignee: THE EYE HOSPITAL OF WENZHOU MEDICAL UNIVERSITY
    Inventors: Yuanbo Liang, Chengtan Liu, Liang Wen, Yanqian Xie
  • Patent number: 10959412
    Abstract: A method for creating an animal model of traumatic optic nerve injury, including fully exposing an internal segment of an optic canal as well as adjacent anterior skull base, posterior ethmoid sinus and lateral sphenoid sinus walls through an ethmoid sinus-sphenoid sinus operation pathway under an endoscope, and impacting different sites of the internal segment of the optic canal with controllable impact force to cause optic nerve injury so as to prepare a controllable and quantifiable TONI bionic elastic injury animal model reflecting contusion to an internal segment of an optic canal in a human TONI clinical injury state. With less intracranial combined injury to the animal, the survival rate is high. Different sites of the optic canal are impacted with quantifiable elastic force for the quantitative and qualitative purposes with respect to the injured parts and the injury degree.
    Type: Grant
    Filed: July 24, 2017
    Date of Patent: March 30, 2021
    Assignee: The Eye Hospital of Wenzhou Medical University
    Inventors: Wencan Wu, Kaihui Nan, Ende Wu, Yuanyuan Chen, Jing Zhou
  • Patent number: 10932900
    Abstract: A method of sutureless intrascleral haptic-hook lens implantation which improves the fixation process of the lens haptics, allowing the lens haptics to be bent and folded back into the vitreous cavity to generate a better stability, avoiding the complication of intrascleral fixation haptic slippage, meanwhile forming a sclera lamellar groove between two adjacent scleral incisions to bury the lens haptics. The method may be adapted to patients in need of intraocular lens implantation without sufficient capsular support, such as aphakia, intraocular lens, lens dislocation, etc. This method enhances the stability and centrality of the lens, the surgical procedures are simple and easy to master, which reduces the operation time.
    Type: Grant
    Filed: April 26, 2019
    Date of Patent: March 2, 2021
    Assignee: THE EYE HOSPITAL OF WENZHOU MEDICAL UNIVERSITY
    Inventor: Ronghan Wu